Regulators catching up on global enforcement
This article was originally published in SRA
Executive Summary
In the globalisation race, regulation often comes a poor second to commercial enterprise. Certainly where drug quality and safety are concerned, the rapid growth in outsourcing of manufacturing and clinical trials to countries like India and China has left regulators in the US and Europe struggling to ensure that standards for good manufacturing practice and good clinical practice are being met.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.